| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.2 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |